Issued to ALEXION PHARM. Application is approved as submitted.
Posted by FDA
June 2, 2026Application
BLA • 125166
Product
SOLIRIS / ULTOMIRIS
Company
ALEXION PHARM
Stage
Final Decision
Assyro regulatory brief
FreeSource facts and Assyro context are separated so you can scan the action quickly without treating analysis as an FDA conclusion.
FDA posted an approval letter for SOLIRIS, ULTOMIRIS on 2026-06-02. This is the document posting date; consult the signed letter for the decision date. The source metadata identifies BLA 125166, BLA 761108 as a supplement. Review the exact FDA letter for the approved conditions and labeling.
Review the exact FDA letter for approved conditions, labeling, and postmarketing requirements.
Open the document workspaceFDA source document
This letter documents an FDA approval action: FDA approved BLA 125166 for SOLIRIS / ULTOMIRIS, sponsored by ALEXION PHARM,. Product may be marketed. Verify current status and labeling in the source letter, since later FDA actions can change them.
BLA 125166 is the application under which FDA issued this approval letter for SOLIRIS / ULTOMIRIS to ALEXION PHARM. FDA posted the letter on June 2, 2026; the posting date is not the decision date.
The sponsor may market the product in line with the approved labeling. Approval letters typically set post-approval obligations: submitting final content of labeling, meeting any postmarketing requirements or commitments listed in the letter, updating Orange Book patent information within 30 days for NDAs, and ongoing annual reporting under 21 CFR 314.81.